Struggling with $5 billion in debt and a maelstrom of legal claims over their alleged role in a nationwide epidemic of opioid abuse, Mallinckrodt has reportedly been consulting with lawyers and restructuring pros to see if they should restructure the company in bankruptcy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,